Vallejo-Torres Laura
Department of Quantitative Methods in Economics and Management, University of Las Palmas de Gran Canaria, Juan de Quesada, 30, 35001, Las Palmas de Gran Canaria, Canary Islands, Spain.
Pharmacoeconomics. 2025 Jan;43(1):109-122. doi: 10.1007/s40273-024-01441-4. Epub 2024 Oct 25.
Knowing the health opportunity costs of funding decisions is crucial to assess whether the health gains associated with new interventions are larger than the health losses imposed by the displacement of resources. Empirical estimates based on the effect of health spending on health outcomes have been proposed in several countries, including Spain, as a proxy to capture these opportunity costs. However, there is a need to regularly update existing health opportunity cost estimates and to explore the role of omitted variable bias in these estimations.
The aim of this paper is to provide an updated and refined estimate of the causal impact of health spending on health in Spain that can be translated into an estimate of the incremental cost per quality-adjusted life-year produced by the Spanish national health system.
We applied fixed-effect models using data for 17 Spanish regions from 2002 until 2022 to estimate the impact of public health spending on health outcomes and explored the extent of omitted variable bias. Changes in these estimates over time were assessed and alternative specifications were tested.
Based on fixed-effect models with control variables, the estimated spending elasticity was 0.061, which translated into an incremental cost per quality-adjusted life-year of approximately €34,000. The bias-corrected elasticity was 0.075, with a corresponding incremental cost per quality-adjusted life-year of €27,000. We found that the estimated impact of spending on health decreases when recent years of data are added, and that the extent of omitted variable bias appears to increase, particularly when adding the COVID-19 pandemic period.
This study provides an updated estimation of the incremental cost per quality-adjusted life-year produced by the Spanish national health system. The estimates provided can be easily updatable as new data become accessible, and the methods applied might be transferable to other settings with similar available data.
了解资金决策的健康机会成本对于评估与新干预措施相关的健康收益是否大于资源转移所带来的健康损失至关重要。包括西班牙在内的几个国家已经提出了基于卫生支出对健康结果影响的实证估计,作为捕捉这些机会成本的一种替代方法。然而,有必要定期更新现有的健康机会成本估计,并探讨遗漏变量偏差在这些估计中的作用。
本文旨在提供西班牙卫生支出对健康的因果影响的最新和精确估计,该估计可转化为西班牙国家卫生系统每产生一个质量调整生命年的增量成本估计。
我们使用2002年至2022年西班牙17个地区的数据应用固定效应模型来估计公共卫生支出对健康结果的影响,并探讨遗漏变量偏差的程度。评估了这些估计随时间的变化,并测试了替代规格。
基于带有控制变量的固定效应模型,估计的支出弹性为0.061,这转化为每质量调整生命年的增量成本约为34,000欧元。经偏差校正的弹性为0.075,相应的每质量调整生命年的增量成本为27,000欧元。我们发现,当加入近年来的数据时,支出对健康的估计影响会降低,并且遗漏变量偏差的程度似乎会增加,特别是在加入新冠疫情期间。
本研究提供了西班牙国家卫生系统每产生一个质量调整生命年的增量成本的最新估计。随着新数据的获取,所提供的估计可以轻松更新,并且所应用的方法可能适用于具有类似可用数据的其他环境。